These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21499787)

  • 1. Social interaction and drug attitude effectiveness in patients with schizophrenia.
    Tsai JK; Lin WK; Lung FW
    Psychiatr Q; 2011 Dec; 82(4):343-51. PubMed ID: 21499787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life.
    Sağlam Aykut D
    J Clin Psychopharmacol; 2019; 39(1):57-62. PubMed ID: 30566417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
    Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
    Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
    BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular paliperidone palmitate.
    Hoy SM; Scott LJ; Keating GM
    CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
    Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
    J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM; Bossie CA; Turkoz I; Alphs L
    Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
    J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible neuroleptic malignant syndrome associated with paliperidone.
    Duggal HS
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):477-8. PubMed ID: 18070861
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
    Üçok A; Saka MC; Bilici M
    Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
    Rusconi AC; Carlone C; Muscillo M; Piccione M
    Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.